Vicki postponed getting a mammogram due to the pandemic, but today she is very grateful that she went in. She was referred for a biopsy that revealed a tiny tumor that was stage zero – also known as ductal carcinoma in situ (DCIS). DCIS is the earliest stage of breast cancer with an almost 100% survival with proper treatment. Part of that treatment is a new test, called DCISionRT®, a molecular test that quantifies the risk of DCIS recurring, as well as predicts the benefit of radiation therapy (RT). Following her lumpectomy, DCISionRT revealed that Vicki would benefit from RT. Vicki’s response, “It was so clear. You could see exactly, in black and white, your chance of recurrence with the surgery, and then with the radiation on top. So, it was possible to make a much better-informed treatment decision.”
Fast-forward 10-months and Vicki is doing fabulous. Her wish, “If I could get just one woman to go in for that mammogram, because early detection if the key.”
To see Vicki’s story https://bit.ly/3FU3c9t
